12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,000 shares of the company’s stock, valued at approximately $49,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Trevi Therapeutics during the 4th quarter valued at about $67,000. SG Americas Securities LLC increased its position in shares of Trevi Therapeutics by 14.5% during the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock valued at $110,000 after buying an additional 3,387 shares during the period. Barclays PLC lifted its holdings in shares of Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after buying an additional 61,317 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Trevi Therapeutics by 220.6% in the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after buying an additional 69,167 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Up 5.3 %

Shares of Trevi Therapeutics stock opened at $5.56 on Monday. The firm has a market capitalization of $537.55 million, a PE ratio of -12.64 and a beta of 0.41. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The business’s 50-day moving average price is $5.30 and its 200-day moving average price is $4.08.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. As a group, analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Activity at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by insiders.

Wall Street Analyst Weigh In

TRVI has been the topic of a number of analyst reports. B. Riley reaffirmed a “buy” rating and set a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 8th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.